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Abstract 
Artificial Intelligence is providing astonishing results, with medicine being one of its 
favourite playgrounds. In a few decades, computers may be capable of formulating 
diagnoses and choosing the correct treatment, while robots may perform surgical 
operations, and conversational agents could interact with patients as virtual coaches. 
Machine Learning and, in particular, Deep Neural Networks are behind this revolution. In 
this scenario, important decisions will be controlled by standalone machines that have 
learned predictive models from provided data. Among the most challenging targets of 
interest in medicine are cancer diagnosis and therapies but, to start this revolution, 
software tools need to be adapted to cover the new requirements. In this sense, learning 
tools are becoming a commodity in Python and Matlab libraries, just to name two, but to 
exploit all their possibilities, it is essential to fully understand how models are interpreted 
and which models are more interpretable than others.  
In this survey, we analyse current machine learning models, frameworks, databases and 
other related tools as applied to medicine - specifically, to cancer research - and we 
discuss their interpretability, performance and the necessary input data. From the 
evidence available, ANN, LR and SVM have been observed to be the preferred models. 
Besides, CNNs, supported by the rapid development of GPUs and tensor-oriented 
programming libraries, are gaining in importance. However, the interpretability of results by 
doctors is rarely considered which is a factor that needs to be improved. We therefore 
consider this study to be a timely contribution to the issue.  
Keywords: drug repurposing, machine learning, personalised therapy, cancer treatment, 
deep learning, high performance computing. 
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1. Introduction  
Cancer has become one of the most common human diseases and causes of death 
(Cronin et al., 2018; Culp, Soerjomataram, Efstathiou, Bray, & Jemal, 2020; Ferlay et al., 
2015). Among other factors, its occurrence is mainly growing because of aging 
(Chiavenna, Jaworski, & Vendrell, 2017). Even though cancer is a disease that affects 
men as well as women, there seems to be a clear relationship between gender and 
incidence. Thus, lung, prostate, colorectal, stomach and liver cancer are predominant 
among men, while breast, colorectal, lung, cervical and thyroid are the most common 
cancers in women (https://www.who.int/health-topics/cancer). Figure 1 depicts the number 
of estimated deaths in 2020 by cancer type collected from the Surveillance, Epidemiology 
and End Results (SEER) database. 
 
Fig. 1. Estimated deaths in USA in 2020 by cancer type and gender. Source: SEER 
database. 
A diverse range of therapies, including chemotherapy, radiotherapy, surgery and 
irradiation, is used in cancer patients depending on tumour type and stage. Unfortunately, 
the success of these treatments is limited because they attack normal and tumoral cells 
equally, which may result in toxicity and make the tumoral cells drug-resistant. In this 
scenario, early detection is a crucial factor for the successful application of therapies, for 
limiting associated side effects and, consequently, increasing the chance of survival 
(Coleman, 2017; Loud & Murphy, 2017). For this reason, providing the physicians with 
appropriate tools for accurate diagnosis and prognosis remains a major challenge in 
cancer research. 
Colorectal cancer (CRC) is the third most common type of cancer worldwide, representing 
10% of all diagnosed cases, and the fourth in the number of deaths it causes (Araghi et al., 
2019; Dekker, Tanis, Vleugels, Kasi, & Wallace, 2019). Furthermore, these figures are not 
very promising because the number of CRC cases is expected to increase by around 60% 
in the forthcoming decade (Arnold et al., 2017). 
As regard the reasons for such disheartening data, bad dietary habits are suspected to be 
behind the growing number of CRC cases reported in recent years but there are other 
reasons, such as the lack of exercise, obesity and smoking that are suspected of causing 
tumours (Kuipers et al., 2015). Moreover, familial and hereditary antecedents have proved 
to influence the incidence of this cancer (Weinberg, Marshall, & Salem, 2017). In an 
attempt to identify reasons, beyond the biological, for the evolution of CRC worldwide, 
Arnold (Arnold et al., 2017) published a study correlating the human development index 
with the incidence and high mortality of CRC, which resulted in the classification of 
countries into three groups with well-defined characteristics. In short, a number of factors 
in our daily lives promote the emergence of colorectal tumours and, although there is no 
clear numerical estimation of how much these factors contribute to the appearance CRC, it 
seems to be in our hands to change the trend. From a more medical point of view, the high 
morbidity and mortality rates could be explained by the fact that malignant CRC tumours 
are considered to be especially complex biologically (García-Figueiras et al., 2018). 
Much effort has been put into predicting CRC or, at least, into predicting the manner in 
which the tumour is likely to progress. Genetic information plays a key role for detecting 
tumoral cells and tissues that can help identify cancer disease at an early stage. The role 
of genetic mutations in CRC has been extensively analysed and several publications are 
available in the literature on this topic (D. Huang et al., 2018; Oh et al., 2018; Ruiz-López 
et al., 2018; Valle, Vilar, Tavtigian, & Stoffel, 2019). Other authors have focused on 
identifying biomarkers with the aim of finding the subset with the highest predictive power 
(Ding, Han, Zhang, He, & Li, 2019; Kather, Halama, & Jaeger, 2018; Lech, Słotwiński, 
Słodkowski, & Krasnodębski, 2016; Yiu & Yiu, 2016). Early identification could increase 
the likelihood of survival and dramatically reduce the mortality rate. Unfortunately, a full 
understanding of cancer cell behaviour is still beyond our grasp, making this a major 
challenge in medicine. 
 
When prevention has failed, the application of individualised therapies is the ideal scenario 
for the treatment of cancer patients. Personalising therapies implies finding the most 
suitable set of drugs and their exact dose for a given patient, based on the available input 
parameters, such as cancer type, tumour size, and whether metastasis is present or not. 
The idea behind this individualisation of therapies is to maximize the effect of drugs, limit 
their side effects, shorten the time necessary to cure the disease and reduce costs. The 
idea that individualised therapies are more cost-effective than generic ones seems 
credible because the same treatment is obviously not suitable for every patient since not 
all cases are similar. Several publications have discussed the direction that medicine is 
taking in this respect (Jackson & Chester, 2015; Jain, 2005; Olin, 2019; Usher-Smith et al., 
2017) and its popularity has grown in recent years. Although all these authors agree that 
personalised treatment will increase the effectiveness of existing drugs, to the best of our 
knowledge, there has been no attempt to put it into practice in the case of cancer 
treatment, making this goal a priority in cancer research. 
 
In this move towards individual therapies, computing sciences have become a close ally of 
health and life sciences and medicinal chemistry. The rapid development of high-
performance computing (HPC) platforms such as parallel and distributed computing have 
found a place to develop in the field of chemical and biological problems. It is well known 
that HPC infrastructures are extensively used to carry out complex scientific calculations 
(Shanyu Chen et al., 2019; Schmidt & Hildebrandt, 2017; Upton, Trelles, Cornejo-García, 
& Perkins, 2016) and their computing power can drastically speed up the resolution of a 
problem (Garg, Arora, & Gupta, 2011; Nobile, Cazzaniga, Tangherloni, & Besozzi, 2017; 
Wang, Ma, Pratx, & Xing, 2011). However, this is not enough: firstly, because the amount 
of medical and pharmacological data available is overwhelming and huge computing 
power is needed to analyse it all; and, secondly, the analysis methods necessary to 
transform such data into real understandable knowledge are very challenging. While HPC 
can help overcome the first difficulty, the application of artificial intelligence (AI), and more 
specifically machine learning (ML), is necessary for the second. Only if HPC and ML work 
together will they be capable of screening the vast chemical space and predict the most 
cost-effective therapy for individual patients (Dilsizian & Siegel, 2014; Pérez-Sianes, 
Pérez-Sánchez, & Díaz, 2019). 
Machine learning experts know that with the right data very efficient predictions can be 
made, as has been demonstrated in several fields such as sports results, injuries, stock 
market movements, text-based emotions, etc. The field of medicine has not been left 
behind in this respect and such technology is already used to diagnose or predict diseases 
such as cancer (Kourou, Exarchos, Exarchos, Karamouzis, & Fotiadis, 2015), making it 
clear that ML, complemented by HPC, represents the future of anti-cancer medicine. 
Already, ML algorithms are very helpful in many cancer-related tasks, such as the 
prediction and diagnosis of the disease, predicting its progression, the search for new drug 
synergies, predicting therapy outcomes and estimating survivability. It is the potential for 
analysing historical data, learning from the analysis and making predictions for future 
cases that makes them suitable for application in cancer research. It might even be 
claimed that ML is the aid that doctors need to increase the accuracy of their predictions 
and decision making, due to its ability to extract knowledge from previous cases. Evidently, 
the output of ML systems has to be transformed to make it understandable by healthcare 
staff; otherwise, we would be wasting an important opportunity.  
This critical review highlights the role of ML in each of the main steps of anti-cancer 
medicine. Section 2 focuses on the needs of doctors, attempting to answer questions like 
“What kind of ML do doctors need?” and “Does ML output need to be adapted to medical 
doctors?”. Section 3 presents a revision of the typical ML algorithms used in each stage, 
each subsection describing the most frequently used approaches, which are condensed 
into a table to facilitate their readability. The most relevant findings observed in Section 3 
are discussed in Section 4. Finally, the main conclusions reached and the future of ML in 
cancer research are summarized. 
2. What kind of ML is important in Medicine/Cancer Prediction and Treatment? 
In this section, we focus on the basic features of an ML system that medical doctors and 
medical/biological researchers are seeking beyond the output that a trained ML system 
already provides. 
The advantages of ML systems stem from the fact that they use thousands of features, 
which they use to produce decisions in a very short time. It is important to note that the 
training stage can be expensive in terms of computing power, while the prediction stage is 
in comparison fast and computationally cheaper. The correlations that the algorithm finds 
between the samples are similar to those found by experienced doctors, who have seen 
hundreds of patients and begun to notice repetitive symptoms or similar values in their 
detailed medical tests, which helps them to make decisions.  
However, no matter how accurate ML systems are, no matter how many lives they can 
save in principle, and no matter if they are based on the doctor’s entire medical knowledge 
if medical/biological researchers do not understand the underlying models and their 
inferences. Only if ML systems cannot be explained, these systems will not be a game 
changer in medicine, nor will medical/biological researchers use them to make everyday 
decisions, condemning the whole approach to failure. To achieve any success, ML 
systems need to gain trust of medical/biological researchers. 
Consequently, our aim was to define four factors that should contribute to the success of 
ML learning systems in the medical domain: i) Output explainability, ii) Linking the 
predictions to the original cases used to produce outputs and iii) Low data hungriness. In 
this survey, we analyse existing approaches with respect to these factors as, only if there 
is a substantial attention paid to all of them will a novel ML approach or system be a game 
changer in a specific clinical situation. Only if the answer to the question “Do doctors need 
to know about and learn ML in the future?” is negative can ML add real value to clinical 
practice.  
 
2.1. Factor One: Output Explainability  
Explainability in Machine Learning or, in AI in general (XAI), is a hot topic, especially when 
it is applied to medicine. AI systems tend to return raw results that are hard to understand, 
which complicates their interpretation by non-expert users, including doctors. Thus, to 
make AI more attractive to healthcare professionals we should answer the question “What 
do doctors need to easily interpret AI predictions?” Explainability or interpretability often 
appears as a desideratum but it is poorly defined (Lipton, 2018). Hence, a clear 
understanding of the term explainability is essential in order to classify existing ML 
approaches. In general, there are two approaches to explainability: model explainability 
and inference explainability (Jacovi, Sar Shalom, & Goldberg, 2018). Model explainability 
relates to understanding how a model behaves in general, whereas inference explainability 
aims to describe how systems decide on each instance. Hence, these are two facets of the 
same problem. However, in both cases, explainability may be obtained by showing 
symbols (e.g., natural language or structured languages such as logical forms) to explain 
models or inferences.  
Since the first AI systems, authors have outlined their stages of inference. For example, 
Swartout et al. (Swartout, Paris, & Moore, 1991) deal with explanations for expert systems, 
Johnson (Johnson, 1994) presents agents that learn to explain themselves, and Lacave 
and Diez (Lacave & Díez, 2002) discuss explanation methods for Bayesian networks (BN). 
In recent years, there has been a strong emphasis on revealing what happens behind the 
black box that uses AI algorithms (Holzinger, Langs, Denk, Zatloukal, & Müller, 2019). This 
is necessary if doctors are to trust the results provided by these algorithms and so use 
them in their daily activities (diagnosis, deciding on the most appropriate treatment, etc.). 
In comparison with other domains, medicine deals with the uncertain, probabilistic, 
unknown, incomplete, imbalanced, heterogeneous, noisy, dirty, erroneous, inaccurate and 
missing data sets in arbitrary high‐dimensional spaces (Holzinger, Dehmer, & Jurisica, 
2014; Lee & Holzinger, 2016). 
Explainable artificial intelligence (XAI) has received much attention in recent years 
(Gunning, 2016). There are two aspects of unsupervised learning models relevant in the 
context of explainability (Holzinger et al., 2019). First, the representations learned in these 
models may show similarities between the data in a class. One such case is the word 
embedding, which can signal semantic similarity between words (Mikolov, Chen, Corrado, 
& Dean, 2013). Second, being able to generate instances that allow us to study the 
differences between data within a class. This is relevant in medicine, where the discovery 
and analysis of disease-related abnormalities are relevant (Schlegl, Seeböck, Waldstein, 
Schmidt-Erfurth, & Langs, 2017). 
Trustworthiness in AI is the ability to evaluate the validity and reliability of an ML system in 
many different input configuration and application environments. This factor is very 
important in the medical environment, particularly in cancer prediction, where it is 
necessary to be able to evaluate exactly the limitations of an ML system and, 
consequently, accurately interpret and trustfully apply ML prediction system outputs. 
Bærøe et al. (Bærøe, Miyata-Sturm, & Henden, 2020) underline the growing importance of 
AI and the relative need for trustworthiness in AI systems, especially in the medical 
environment. In the same work, the authors analyse the report: “Ethical guidelines for 
trustworthy artificial intelligence” published by the European Commission in 2019 
(https://ec.europa.eu/futurium/en/ai-alliance-consultation) and highlight the need for 
“globalising” the guidelines at both European and international level.  
2.2. Factor Two: Linking to original cases to produce outputs 
AI systems often focus on the outputs but do not explain how much each input participates 
in the result. In a medical context, this correlation between inputs and outputs may be 
necessary to identify the reasons leading to a given decision. 
Assignment methods try to link a certain output of the deep neural network with input 
variables (Holzinger et al., 2019). In another paper (Sundararajan, Taly, & Yan, 2017), the 
authors analyse the change in output gradients depending on the change in input 
variables. In this way, the authors propose a result based on the data that were used as 
the input of an algorithm and try to make a link between these data and the result 
obtained.  However, in the medical field, although we will can still explain the results 
obtained and see a link with similar cases that formed the basis of a decision formulated 
by the AI algorithms, besides the huge opportunities that AI provides, there will always be 
the possibility of making a mistake and exposing the patient to certain risks (Oakden-
Rayner & Palmer, 2019). 
2.3. Factor Three: Data Hungriness 
With the widespread application of computer technology in the medical field, the amount of 
medical data available has increased dramatically, and analysis methods are already in 
use for the intelligent assessment of medical health. In coming years, we expect the 
volume of medical data to increase even more, ranging from terabytes to petabytes and 
even yottabytes (Archenaa & Anita, 2015; Hermon & Williams, 2014; Ristevski & Chen, 
2018).  
However, due to the mixed format of medical data, incomplete records, and the noise 
present in them, it is still difficult to analyse large amounts of medical data (Sun, Liu, 
Wang, Lian, & Ma, 2019). Because traditional ML methods cannot efficiently extract a rich 
body of information from large medical databases, Deep Learning (DL) methods are used 
to build a hierarchical model by simulating the human brain. Increasingly, DL models use 
large medical databases, from which they select and optimize parameters and 
automatically learn the process of pathological analysis of doctors (Hassan, Hassan, & 
Kholief, 2018). Based on these models, the disease in question is in an intelligent way and 
an early diagnosis can be made. Thus, the pressure on the activities of doctors is 
considerably reduced and the efficiency of their work can be improved. 
3. Application of ML approaches in cancer cases 
In this section, a number of cases will be discussed to illustrate how ML can help doctors 
in the different stages of cancer evolution, from its diagnosis to the prediction of survival 
chances. Each section focuses on one of the main steps targeted by ML in healthcare 
contexts. Tables 1 to 6 summarize a detailed collection of works related with the topic of 
discussion. The datasets column describes the original source of data to reference a 
specific dataset, a full database, a citation, a project, or the institution that collected the 
samples. The column entitled “Exp?” means whether the interpretability of the results by 
non-experts is considered in the paper or not. Other relevant information, such as the AI 
approaches and the software tools used, are also reported. To facilitate the readability of 
the examples, we present the works in a short table per section. 
 
3.1. Predict the possibility of cancer 
Cancer 
type 
AI 
approa
ch 
Datasets Software Trainin
g data 
set size 
Data 
types 
Exp? Referenc
e 
Lung CNN 
 
BRFSS Caffe 235673 Text Yes (Songjing 
Chen & 
Wu, 
2020) 
Any RF COSMIC, dbSNP 
 
R, 
HMMER, 
Dojo 
200,  
800 
Text 
 
No (Kaminke
r, Zhang, 
Watanab
e, & 
Zhang, 
2007) 
Any SVM Cosmic, 
SwissVar, Swiss-
Prot 
 
Libsvm 
 
 
6326 
 
 
Text No (Capriotti 
& Altman, 
2011) 
Breast, 
Thyroid, 
Kidney 
RF TCGA:BRCA, 
TCGA:THCA, 
TCGA:KIRP 
Java, 
Weka, 
YARN, 
MLlib 
 
 
 
897, 
571, 
321 
 
 
Text No (Celli, 
Cumbo, 
& 
Weitsche
k, 2018) 
 
DT TCGA:BRCA unknown 
 
897 Text No 
 
SVM TCGA:BRCA unknown 
 
897 Text No 
 
BN TCGA:BRCA unknown 897 Text No 
CRC BN NSHDS R, 
Visualizatio
ns with 
Cytoscape 
1676 Text Yes (Myte et 
al., 2017) 
Breast ANN  
Private 
 
Matlab 62219 Images, 
Text 
No (Ayer et 
al., 2010) 
CNN, 
SVM 
 
unknown R 500 Images, 
Text 
No (Heidari 
et al., 
2018) 
CNN, 
KNN 
unknown 
 
R 500 Images, 
Text 
No 
GBM, 
SVM 
 
KBCP, 
OBCS 
 
 
XGBoost, 
Sklearn, 
esyN, 
Matplotlib, 
Python 
696, 
923 
 
Text Yes (Behrava
n et al., 
2018) 
Gastric GBM Private XGBoost 1431 Text No (Taninag
a et al., 
2019) 
LR Private 
 
unknown 1431 Text No 
Skin ANN NHIS unknown 462630 Text No (Roffman
, Hart, 
Girardi, 
Ko, & 
Deng, 
2018) 
Ovarian KNN, 
LDA, 
SVM, 
ELM 
IOTA tumor images 
database 
Matlab 348 Images No (Martínez
-Más et 
al., 2019) 
Cervical CNN Private Caffe 20000 Images No (Martínez
-Más et 
al., 2020) 
Table 1. Review of publications whose main topic is ML and cancer risk prediction. 
Currently, most of the studies performed for predicting the possibility of cancer are based 
on the analysis of genetic data and mutations. Kaminker et al. (Kaminker et al., 2007) 
developed CanPredict software to identify and predict whether certain mutations are 
associated with tumours or not. The software combines the Sorting Intolerant From 
Tolerant (SIFT), LogR.E-value score, and Genetic Ontology Similarity Score (GOSS) 
methods by applying an advanced Random Forest (RF) classification scheme. Capriotti 
and Altman (Capriotti & Altman, 2011) used support vector machines (SVM) to analyse 
different databases, each created with an equal number of cancer driver Single Amino 
Acid Polymorphisms (SAPs) and neutral SAPs. Using this technique, it is possible to 
predict whether a given missense SAP is neutral or is involved in cancer appearance. In 
their study, the authors achieved an effectiveness greater than or equal to 90% in the 
overall predictions. 
 
Taninaga (Taninaga et al., 2019) describe how a set of characteristics related to gastric 
cancer can be processed using extra gradient boosting decision (XGBoost) algorithms or 
logistic regression (LR) methods to predict whether a patient is at risk of developing the 
disease over the next 122 months. In this study, 10 models were developed. For the first 
five, the authors used XGBoost: the first model only took into account Helicobacter 
infections, while to the second they added data on chronic atrophic gastritis, in the third 
they included endoscopic findings, in the fourth they added biological background factors 
and in the fifth they also included blood tests. The other five models were identical applied 
linear logistic regression instead of XGBoost. The performance of each model was 
measured using the area under the curve (AUC) value. As a result of the research, the 
most influential characteristics in the development of gastric cancer were seen to be the 
mean corpuscular volume, the proportion of lymphocytes, age, body mass index (BMI), 
and postgastrectomy. Finally, AUC values of 0.899 and 0.874, respectively, were obtained 
with the 5th and 10th models, the authors concluding that with these models it is likely to 
predict whether a patient might suffer from cancer. 
 
According to the American Cancer Society, 3.3 million people are diagnosed with skin 
cancer annually. A prediction of the risk of suffering Non-Melanoma Skin Cancer (NMSC) 
was made (Roffman et al., 2018) using 13 personal data of patients that can easily be 
obtained from an Electronic Medical Record (EMR): gender, age, BMI, diabetic status, 
smoking status, emphysema, asthma, race, Hispanic ethnicity, hypertension, heart 
diseases, vigorous exercise habits, and history of stroke. These input parameters were 
first normalised to values between 0 and 1 and an artificial neural network (ANN) model 
was developed based on one input layer with 13 nodes, two hidden layers with 13 nodes, 
and one output node. The authors used 462630 cases, taking 70% of the cases for 
training and the remaining 30% for validation, and obtained an AUC value of 0.81. The 
study concluded that by including the two most important factors that should be taken into 
account in skin cancer, i.e. radiation and personal history, risk predictions of the model 
could very likely be improved. 
 
Martínez-Más et al. (Martínez-Más et al., 2019) combined different ML techniques with 
features obtained by Fourier transform (FT) to classify ovarian tumours as benign or 
malignant, using ultrasound images. After extracting 187 features from the ultrasound 
images using FT, they were used as input features for KNN, LD, SVM and ELM. For this, 
different kernels were analysed to obtain the optimal configuration, and it was seen that 
the combinations of FT with LD, SVM or ELM are good classifiers for biomedical images, 
providing an accuracy of more than 85%. 
 
Breast cancer (BC) is one of the most common types of cancer in women. For prediction 
purposes, a regular analysis of mammographic images is required. To estimate the 
probability of malignancy of the tumour there are three categories: prognostic models, 
computer-aided detection, and computer-aided diagnosis. Ayer (Ayer et al., 2010) 
proposed a method for accurately predicting BC using ANNs, with particular emphasis on 
calibration made by means of the Hosmer–Lemeshow goodness-of-fit test. This generates 
a network topology with three layers: the first one with 36 input nodes (mammographic 
descriptors, demographic factors, and BI-RADS), a hidden layer with 1000 nodes and an 
output layer with 1 node. Later, they trained the network using a cross-validation method 
on 62219 registers. Next, they compared the results obtained through their model with the 
prediction experience of eight radiologists. The fact that the ANN obtained an AUC value 
of 0.965 and the radiologists a value of 0.939, demonstrates the good predictive 
capabilities of ANN, which can therefore be considered a reliable support tool. 
 
Predictions of the risk of developing BC in the short term can be made by comparing the 
distribution of volumetric breast density of both breasts based on mammographic image 
analysis (Heidari et al., 2018). The authors proposed a model based on a Convolutional 
Neural Network (CNN), which converts an image into a characteristics vector, then applied 
a Locality Preserving Projection (LPP) algorithm to reduce the features obtained by the 
network, finally obtaining a vector with 44 characteristics. Classification was then carried 
out, comparing two classification methods, SVM and k-nearest neighbours (KNN). The 
model was trained through a cross-validation using 500 mammographic images, which 
provided an AUC value of 0.62 for SVM and 0.60 for KNN. In order to further optimize the 
accuracy of the model, the AUC values were calculated for each of the 44 characteristics 
and then sorted according to these values. Subsequently, the least relevant characteristics 
were eliminated, by testing the model based on a range of 2 to 10 characteristics. With 10 
features and using KNN, an AUC value equivalent to 0.64 was obtained, which was better 
than when using 44 features. The best configuration was achieved using LPP-KNN, 
reducing the regenerated features to four.  This gave an AUC value of 0.68 for the short-
term prediction of BC (less than 5 years). 
 
The risk of developing BC can be predicted through the identification of Single Nucleotide 
Polymorphisms (SNPs) in DNA that contribute most to its development (Behravan et al., 
2018). To identify them, a three-stage protocol is implemented: (i)  the SNPs are selected 
using a gradient boosting classification technique: XGBoost; (ii) based on the XGBoost 
output data, an adaptive iterative search for SNPs is made, sorting the results downwards 
according to their scores; the M best-scored results and the M worst-scored ones are 
selected and are separately ordered from lowest to highest; this process is repeated, 
increasing the size of M until the both lists overlap; (iii) the top SNPs are chosen and 
classified with SVM representing an optimal group that can potentially predict the risk of 
BC. The protocol is implemented in Python with the libraries sklearn, xgboost among 
others and can be downloaded from github. 
 
DNA methylation is known to play a major role in tumorigenesis. BIGGIOCL (Celli et al., 
2018) is a tool that can be used to analyse hundreds of thousands of individual data in a 
few hours. Although it was designed to analyse DNA and CpG Islands, the author 
specifies that it could be adapted to other fields. The tool, developed in Java and based on 
the MLlib learning library, allows parallelization of work in multiple machines. When 
developing the software one of the reasons for implementing RF was its parallelization 
capability that allows a forest tree to be executed in each node and the information to be 
sent to the master node. As it is based on MLlib it can be used in Yet Another Resource 
Negotiator (YARN) environment. In the publication the authors analysed data from 
HumanMethylation450 to check its relationship with BC and obtained a direct relationship 
with the genes RP53, PIK3CA, BRCA1, BRCA2 and BDNF, results that match those 
previously published by other authors. 
 
Another type of cancer that is frequent in both men and women is CRC. Myte (Myte et al., 
2017) carry out the first study relating a One-carbon metabolism (1CM) pathway to cancer 
risk in humans by applying a BN. The observed relationship between compounds of 1CM 
and CRC, and the lack of empirical studies proving the impact of 1CM and SNPs on CRC 
motivated this work. The study collects data from blood samples, one per patient, and 
uses a BN to relate population-based data, SNPs and the metabolic pathways involved in 
1CM. The authors suggested that the most important factors in colorectal tumorigenesis 
are the associations between folate, vitamin B6 and vitamin B2, and concluded that these 
compounds should be taken into account in future studies of 1CM and the development of 
CRC.  
 
Lifestyle is important for disease prevention. In the case of lung cancer particularly, there 
are certain habits or external factors that can increase the risk of contracting the disease. 
In the study of Chen and Wu (Songjing Chen & Wu, 2020) a set of data concerning 
demographics, disease, radiation, behaviour, environment, and smoking was analysed in a 
group of adult patients. The authors used a CNN to identify which of these factors are the 
most important in the development of this type of cancer. The study divided the samples 
into four groups: (i) men over 64 years, (ii) women over 64 years, (iii) all those over 64 
years, and (iv) all those over 17 years. The four sets of data were then converted into 
Hierarchical Data Format 5 (HDF5), which is designed to store and organize large 
amounts of data and is used by Caffe, a Deep learning framework, to import the data into 
their CNNs. After training the model with a cross-validation, it achieved an AUC prediction 
value of 0.913 and, of all the risk factors for lung cancer examined in those over 64 years 
of age, smoking was the most important. 
 
In Martínez-Mas et al. (Martínez-Más et al., 2020), the authors propose a novel method for 
the early detection of cervical cancer, which is one of those with high mortality in women. 
Frequently, the automatic classification of medical images does not pre-clean the images 
to remove overlaps, which does not reflect the reality of the images obtained directly from 
the medical samples. To overcome this issue, the authors implemented an artificial cell 
merger approach to improve the efficiency and realism of the classification model using 
CNN and without ruling out blurred, overlapping cells, etc. This approach showed a 
classification accuracy of 88.8%, obtaining a sensitivity and specificity of 0.92 and 0.83, 
respectively. 
 
3.2. Predict cancer recurrence 
Cancer 
type 
AI 
approach 
Datasets Software Training 
data set 
size 
Data 
types 
Exp? Reference 
CRC KNN, 
SVM, 
GBM, 
ANN, DT, 
RF 
GEO, 
ArrayExpress 
R 50 Text Yes (Lu et al., 2020) 
LR, DT, 
GBM 
BioStudies 
database 
Python, 
R 
800 Text Yes (Y. Xu, Ju, 
Tong, Zhou, & 
Yang, 2020) 
Breast SVM, 
ANN, 
Regression 
unknown SPSS, R 733 Text No (J. Kim & Shin, 
2013) 
SVM, 
ANN, DT 
ICBC Weka 1189 Text No (Ahmad, 
Eshlaghy, 
Poorebrahimi, 
Ebrahimi, & AR, 
2013) 
SVM, RO BioBIM Java 318 Text Yes (Ferroni et al., 
2019) 
Breast SSL GEO, I2D C++ 194988 Text Yes (C. Park, Ahn, 
Kim, & Park, 
2014) 
CRC 
Oral BN, ANN, 
SVM, DT, 
RF 
unknown unknown 86 Text, 
Images 
Yes (Exarchos, 
Goletsis, & 
Fotiadis, 2012) 
Cervical SVM, DT, 
ELM 
Chung Shan 
Medical 
University 
Hospital 
Tumor 
Registry 
unknown 168 Text Yes (Tseng, Lu, 
Chang, & Chen, 
2014) 
Table 2. Summary of studies analysed in Section 3.2 about cancer recurrence. 
 
Once the cancer is diagnosed, one of the main concerns is the possibility of recurrence or 
metastasis. In this line, Exarchos et al. (Exarchos et al., 2012) used a data set comprising 
clinical, image and genomic data to provide a multiparametric system to detect recurrence 
in squamous cell carcinoma using BN, ANN, SVM, decision trees (DT) and RF classifier 
algorithms and ROC curve assessments. The best results were obtained for the BN 
classifier (78.6% for clinical data, 82.8% for images and 91.7% for genomic data). Kim et 
al. (W. Kim et al., 2012) studied the recurrence of BC over 5 years using SVMs, ANNs, 
and regression analysis; in this case, the SVM model gave the best results in terms of 
accuracy (89%). In the same study, it should be noted that selection of the characteristics 
of the models was based on the mutual information provided by the input characteristics. 
In the same line of detecting recurrent BC, Park et al. (C. Park et al., 2014) used genetic 
information to create a graphical model based on semi-supervised learning (SSL) through 
gene pairs that indicate strong biological interactions, in this case for both breast and colon 
cancer. This graphic model proved to be quite accurate in predicting the recurrence of 
breast and colon cancer (80.7% and 76.7%, respectively). This SSL technique was seen 
to very interesting when very few labelled samples are available, which is a fairly common 
problem for this type of data set. 
 
In Ahmad et al. (Ahmad et al., 2013), three ML methods (DT, ANN and SVM) were 
compared for predicting for BC recurrence by analysing sensitivity, specificity and 
accuracy. The C4.5 algorithm was used in DT. Accuracy of 0.936, 0.947 and 0.957, 
respectively, were obtained. This work showed that SVM had the lowest error rate and the 
highest accuracy for predicting the recurrence of BC.  In Tseng et al. (Tseng et al., 2014), 
SVM, DT and Extreme Learning Machine (ELM) are used to predict the recurrence of 
cervical cancer. Of these three methods, DT obtained the best results, especially when 
using the C5.0 algorithm (92.44 % accuracy). The following were analysed in the study: 
Pathologic Stage, Pathologic T, Cell Type and RT Target Summary.  
 
Another way of approaching cancer prediction is through making individual predictions for 
each patient. Ferroni et al. (Ferroni et al., 2019) studied this approach using SVM and 
Random Optimization (RO) to predict BC in individual patients. In addition to prediction, 
the model allowed patients with low and high risk of cancer progression to be 
differentiated. The authors concluded that the use of ML algorithms (specifically SVM) with 
RO, allows the creation of an efficient model for customization in the prediction and 
recurrence of BC. 
 
Two studies by Lu et al. and Xu et al. (Lu et al., 2020; Y. Xu et al., 2020) worked on the 
early identification of CRC recurrence. In the first paper, several treatments were 
analysed, and good results were observed in patients who are sensitive to FOLFOX (5-FU, 
leucovorin and oxaliplatin). The authors used ML algorithms (more specifically KNN, SVM, 
GBM, ANN, DT and RF) to identify the differences in genes between patients who respond 
to FOLFOX and those who do not respond in cases of CRC recurrence. They concluded 
that SVM and RF are the most effective ML methods for predicting FOLFOX response. In 
the second paper, too, ML techniques (LR, DT, Light GBM, GBM) were used to study the 
impact of treatments once CRC had been detected. Light GBM and GBM were found to be 
the most efficient for detecting the reappearance of CRC, and the treatments that most 
influence the reappearance of tumours were chemotherapy, age, carcinoembryonic 
antigen and anaesthesia time. 
3.3. Predicting cancer progression 
Cancer 
type 
AI 
approach 
Datasets Software Training 
dataset 
size 
Data 
types 
Exp? Reference 
Lung RF Multicenter 
Clinical 
Trials 
Matlab2016, 
SPSS23 
72, 32, 
31 
Images 
No (Dercle et 
al., 2020) 
Lung TL TRACERx, 
(Yates et 
al., 2015), 
(Gerlinger 
et al., 
2014) 
ClonEvol 768 
CCF, 
binary 
data 
Yes (Caravagna 
et al., 
2018) 
Breast 
Renal 
CRC 
Lung RNN TCGA Matlab 506, 253 
Numbers 
No (Auslander, 
Wolf, & 
Koonin, 
2019) 
CRC 
Breast ANN (Albertazzi 
et al., 
1998) 
unknown 16 
Numbers 
No (Grey, 
Dlay, 
Leone, 
Cajone, & 
Sherbet, 
2003) 
Head 
and 
Neck 
LR GSE57441, 
GSE9844 
GraphPad 
Prism 
330 
Mass 
spectra 
No (Ishii et al., 
2020) 
Skin Weka-
FCBF, 
SVM, PCA, 
ExtraTrees, 
TCGA caret, scikit, 
OmicsMarkeR, 
Rtsne, 
scatterplot3d 
371, 
354, 371 
Numbers 
No (Bhalla, 
Kaur, Dhall, 
& Raghava, 
2019) 
KNN, RF, 
LR, Ridge 
Table 3. Works applying ML to forecast cancer progression. 
 
Tumours can change over time, getting bigger, becoming malignant or undergoing 
metastasis (McGranahan & Swanton, 2017) in an evolutive process that involves 
cancerous cells (Greaves & Maley, 2012). Tumours evolve in different ways in different 
patients. The REVOLVER (Repeated EVOLution in cancER) method (Caravagna et al., 
2018) applies the so-called Transfer Leaning (TL) approach to forecasting cancer 
progression. While the standard procedure infers uncorrelated models for each individual 
patient depicted by phylogenetic trees containing noisy data, REVOLVER uses TL to 
correlate models obtained from different patients and identify similarities in those tumours 
that evolve in a similar manner. The idea behind TL is to store the knowledge obtained 
while solving one problem and to apply this knowledge, when possible, in the resolution of 
a similar task. Thus, the knowledge extracted from one sample is transferred to another. 
As input, REVOLVER uses a set of Cancer Cell Fractions (CCF) or any other genetic 
alteration that can be represented in binary format. It then follows a two-step process: i) it 
calculates a set of correlated evolutionary trees, which are numerically scored, describing 
the evolution of each patient’s tumour; and ii) it computes the evolutionary trajectories for 
each group of input alterations depicted in a tree that shows the number of times an 
alteration occurs among other values. This method was used to analyse a collection of 
datasets for lung, breast, renal and colorectal cancer based on 768 samples, and identified 
interesting genomic trajectories that were judged to merit further study (e.g. 
CDKNA→TP53→TERT, TP53→PIK3CA→-8p→+8q).  
 
Alternative to TL for studying mutation timelines are Long Short-Term Memory (LSTM) 
networks, which are a type of recurrent neural network (RNN) with the ability to learn long-
term dependencies from a sequence of events. LSTM takes advantage of the temporal 
nature of mutation trajectories. With this type of algorithm, mutations can be sorted by 
occurrence time to provide an explanation of tumour evolution (Auslander et al., 2019). 
The authors trained an LSTM of 5 hidden layers aiming to predict the number of mutations 
present in each tumour, the so-called mutational load. The model was trained on two 
datasets containing CRC and lung cancer samples. In less than 100 epochs they reach an 
AUC of 0.95. It is also possible to predict the genes that are present in such mutations and 
identify a set present in both types of cancer (e.g. titin, mucin-16, nesprin-1). Finally, the 
authors reported that the last 20 mutations are highly correlated with the mutational load. 
To validate their model, they implemented an SVM model that exhibited lower 
performance than LSTM, probably because they studied a non-linear relationship between 
mutations. 
 
The state of a BC usually depends on several factors, such as the tumour size and 
cellularity, the presence of tumoral cells in the lymph nodes being the most reliable marker 
and the expression of S100A4 and nm23 genes the most effective predictors of their 
status. In order to investigate the predictive power of these genes and tumour size and 
grade a set of 15 ANNs was trained on 16 BC samples and tested against another 16 
(Grey et al., 2003). The results confirmed the expression of S100A4 and nm23 genes as 
the most effective predictor and that the inclusion of other markers could improve the 
accuracy (e.g. ER/PgR expression). 
 
Simpler ML approaches, such as LR, can also help in predicting cancer progression (Ishii 
et al., 2020). The method works in the knowledge that Transforming Growth Factor beta 
(TGF-β) is involved in the acquisition of heterogeneity by tumours (Hall & Massagué, 
2008). This fact means that TGF-β is responsible for promoting tumour evolution, thus 
complicating cancer prognosis. The activation of TGF-β signalling contributes to the 
acquisition of malignant properties by head and neck squamous cell carcinoma (HNSCC). 
However, the effects of TGF-β on lipid metabolism remain unclear. In this context, the 
authors aimed to develop an ML-based algorithm to detect intratumoral TGF-β-stimulated 
areas in clinical HNSCC tissue without recourse to a conventional immunohistological 
examination. For this purpose, Logistic Regression of the mass spectra of HNSCC-
stimulated and non-stimulated human cells was carried out on the public datasets 
GSE57441 and GSE9844. The LR algorithm accurately segregated stimulated and non-
stimulated cells reaching a classification accuracy of up to 98%. This finding demonstrates 
that simple ML approaches, despite their limitations, can also be helpful in predicting 
cancer progression. 
 
Metastatic Skin Cutaneous Melanoma (SKCM) has been demonstrated to arise from 
factors such as the expression of mRNAs and miRNAs and aberrations in methylation 
patterns (Greenberg, Chong, Huynh, Tanaka, & Hoon, 2012; Mazar et al., 2011). To 
understand how skin melanoma progresses a combination of feature selection methods 
and ML classifiers has been used (Bhalla et al., 2019). The data, including mRNA, miRNA 
and methylation expressions from The Cancer Genome Atlas (TCGA) database, were split 
into 80% for training and 20% for testing, giving training datasets of 371, 354 and 371 
samples respectively. First, three feature selection methods, namely Weka-FCBF, SVM 
with L1 regularization (SVM-L1) and Principal Component Analysis (PCA), were applied to 
reduce the number of input features so that subsequent analysis could focus on the most 
discriminative characteristics. In this step, SVM-L1 outperformed the other methods by 
selecting the 17 features that were used in the next stage. The Jaccard index was 
calculated to select the best method. Secondly, six classification models were developed 
to support vector classification with weight (SVC-W) performed best, obtaining 0.95 AUC 
and 89.4% accuracy in an external validation test. The other classifiers were ExtraTrees, 
KNN, RF, LR and Ridge classifier. The models were assessed using different metrics, 
including AUC, the Matthews coefficient, sensitivity, specificity and accuracy. As a 
conclusion, the authors reported a collection of genes that could be considered relevant 
markers of cutaneous melanoma metastasis (e.g. ESM1, NFATC3, C7orf4).  
3.4. Calculating drug doses or drug combinations 
It used to be commonly accepted that the administration of drug combinations rather than 
providing monotherapy can increase treatment efficacy (Mokhtari et al., 2017). This 
approach is nowadays limited by the huge size of the chemical space that makes the 
identification of novel drugs very difficult and, consequently, complicates the choice of 
effective drug combinations. In order to perform a cost-effective screening of this chemical 
space, DL methods are gaining in importance. For example, the DeepSynergy tool (Preuer 
et al., 2018) aims to predict the most efficacious anti-cancer multi-drug treatments by 
means of DL. DeepSynergy provides an ANN, which is implemented with the modern 
TensorFlow framework, and outperformed other ML methods, such as gradient boosting 
machines (GBM), RF, SVM and Elastic Nets, in a benchmark on the largest synergy 
dataset. However, the performance all these methods decreased when exploring new 
datasets of different sizes and data distributions, which is one of the typical problems of 
ML approaches which remains a challenge today. In the same line, Celebi (Celebi, Bear 
Don’t Walk, Movva, Alpsoy, & Dumontier, 2019) published a study to identify functional 
anti-cancer dual therapies, an approach whereby two single-target drugs work in synergy 
to cure a disease. The above authors evaluated five ML methods (LR, Lasso, SVM, RF 
and GBM) implemented with the sklearn and xgboost Python libraries. All the models were 
trained on a novel dataset released by AstraZeneca and the Dialogue for Reverse 
Engineering Assessments and Methods consortium (Menden et al., 2017). The 
assessment showed that GBM outperformed the other methods in synergy identification. It 
is interesting to mention that the study included a variant of LR, the so-called Lasso 
(Tibshirani, 1996), which is a regularized version of LR that reduces overfitting in the 
model. 
Cancer 
type 
AI 
approach 
Datasets Software Training 
dataset 
size 
Data types Exp? Reference 
Prostate ANN UCSD 
#140520 
study 
unknown 66 Text, 
Images 
unknown (Shiraishi, 
Tan, Olsen, 
& Moore, 
2015) 
ANN UCSD 
#140520 
study 
unknown 66 Text, 
Images 
No (Shiraishi & 
Moore, 
2016) 
CNN unknown Keras, 
Tensorflow 
72 Images No (Nguyen et 
al., 2019) 
Breast DSS Local 
database 
unknown unknown DB-stored 
medical 
records 
Yes (Musen, Tu, 
Das, & 
Shahar, 
1996) 
Any LR, SVM, 
RF, GBM 
AstraZeneca, 
DREAM 
consortium 
sklearn, 
xgboost 
2790 Numbers Yes (Celebi et 
al., 2019) 
MVA on 
Undirected 
Graphs 
GDSC, 
CCLE, CTRP  
 
R, 
Matplotlib, 
Graphviz  
 
700 CSV, Text Yes (Keshava et 
al., 2019) 
ANN (O’Neil et al., 
2016) 
TensorFlow  23062 Compounds, 
Cell lines 
Yes (Preuer et 
al., 2018) 
RF Princess 
Margaret 
Cancer 
Centre  
unknown  383 Images No (McIntosh & 
Purdie, 
2016) 
CNN PASCAL 
VOC 2012  
TensorFlow  1464 Images No (L.-C. Chen, 
Papandreou, 
Kokkinos, 
Murphy, & 
Yuille, 2017) 
CNN PASCAL 
VOC 2012  
 
Caffe, 
TensorFlow  
 
1464 Images No (L.-C. Chen, 
Papandreou, 
Schroff, & 
Adam, 2017) 
ANN NCI 
database 
unknown 141 Text Yes (Weinstein 
et al., 1992) 
Table 4. Manuscripts applying ML to estimate drug doses or finding drug combinations for cancer 
therapies. 
Besides deciding on the drug combination to be administered, identifying the exact dose is 
crucial for creating personalised cancer therapies. However, despite the importance of 
these points, research into them lags behind estimating cancer risk or predicting therapy 
outcome. EON software (Musen et al., 1996), a component-based decision support 
system (DSS) that was developed to build healthcare protocols at a high level of 
abstraction, represented a first attempt to use AI to build reusable software capable of 
helping doctors. Its modular design makes it easy to add and replace components, and the 
graphical interface means that it is accessible to any user, even those lacking advanced 
computer skills. A major advantage of EON is that, once designed, the protocols can be 
reused for any disease with minimal adaptations; for example, different types of cancer or 
AIDS might share the same protocol. With regards to drug dose estimation and the optimal 
application time, EON includes the Chronus temporal query system, which implements a 
specific algebra for writing temporal queries and can be extended with the Catenation 
operator. This operator is able to identify adjacent periods and merge them into a single 
one, making it possible to know when and for how long a patient was given a certain drug 
combination. This information, along with the therapy outcomes for the same periods, can 
help analyse the effectiveness of a drug synergy, providing useful information for future 
cases.  
A recently published work (Kearney, Chan, Valdes, Solberg, & Yom, 2018) summarizes 
the main advances of AI for treating head and neck cancer patients. A key factor when 
planning treatments for this cancer is the intensity modulated radiotherapy (IMRT) dose 
prediction. The manuscript describes the way ANN (Shiraishi & Moore, 2016; Shiraishi et 
al., 2015), CNN (L.-C. Chen, Papandreou, Kokkinos, et al., 2017; L.-C. Chen, Papandreou, 
Schroff, et al., 2017; Nguyen et al., 2019) and tree-based methods (McIntosh & Purdie, 
2016) are currently applied to resolve classification problems from a collection of images. 
The aim of this sort of protocol is to identify the most effective dose for each patient. Tree-
based methods try to mimic the thinking of an expert clinician looking at a set of images of 
a new patient, identify a similar past patient with the most similar images, and map the 
dose distribution administered to the former patient in order to assess the optimal 
treatment to be applied with the new patient. To do this, a collection of features is 
extracted from the images to build a dataset of structured data that can be handled by 
most ML algorithms. This approach reached 78.68% and 86.83% accuracy in breast and 
prostate cancer, respectively, when the Gamma metric was used. The main drawback of 
tree-based algorithms that work in this way is that their accuracy is closely coupled to their 
core steps: extracting descriptive features from the source images, identifying a similar 
patient on the basis of such descriptive features and adapting the past dose to the new 
patient. The alternatives to the tree-based methods used in the above work are fully 
connected ANNs with two layers, which are easy to train but which do not conserve 
memory and may suffer overfitting. Whatever the case, the prediction error reported was 
lower than 10% (Shiraishi & Moore, 2016). Fortunately, CNNs are very good for predicting 
volumetric information, the most suitable types being Tiramisu and Dilated CNNs (DCNN). 
Tiramisu models work in two steps: i) encoding the input image to extract the most 
descriptive features; and ii) decoding the information to restore it to the initial size. When 
the dose volumes are consistent with respect to the anatomy (e.g. in prostate cancer), 
Tiramisu models are the preferred option (Nguyen et al., 2019), otherwise (e.g. head and 
neck cancer), DCNNs are preferable. 
Frequently, gene mutations are detected in cancer patients, and discovering the 
relationship between these genetic variations and drug responses has led to the ability to 
identify which patients might profit most from certain drug synergies. However, the results 
of clinical trials in their advanced stages must exhibit a significant improvement over 
standard therapy. Thus, clearly defining groups of patients in which a novel drug may be 
more effective than the existing ones could help lead to individualised therapies, and, as a 
consequence, this has become a target of ML. An unsupervised learning approach based 
on multivariate analysis (MVA) of undirected graphs (Keshava et al., 2019) was performed 
to classify patients into well-defined subpopulations. The statistical methods were 
implemented with R packages and the input datasets were collected from the GDSC 
(https://www.cancerrxgene.org/), CCLE (https://portals.broadinstitute.org/ccle) and CTRP 
(https://portals.broadinstitute.org/ctrp/) databases. As result of this work, the SEABED 
(Segmentation and Biomarker Enrichment of Differential Treatment Response) platform 
was developed and used in several examples, in one of which the authors aimed to 
assess the response to a combination of drugs, namely A and B. To accomplish this, they 
segmented patients into subpopulations depending on their response to the therapies, 
considering AUC and IC50 as metrics. They also provided a graphical representation of the 
results in a tree whereby the identified subpopulations were coloured depending on the 
exhibited sensitivity to both, A, B or no drugs, which is important for facilitating 
interpretation of the results. Then, the authors chose a BRAF and a MEK inhibitor and 
discovered that the subpopulation sensitive to A was enriched for BRAF mutations and the 
one sensitive to B was enriched for MEK mutations. This approach is generic enough to be 
used for the analysis of any type of cancer sample, independently of its particular 
characteristics and can also be of great use for predicting tumour progress.  
As can be inferred from Table 4, image processing is a key procedure when estimating 
drug doses and finding effective drug combinations. To satisfy the need for powerful image 
processing algorithms, CNNs have shown themselves to be alternative to traditional 
ANNs. In parallel, new frameworks (e.g. TensorFlow, PyTorch) have been developed to 
exploit all the computing power of graphical processing units (GPUs) and accelerate image 
analysis. When there are no images available or their inspection is not suitable, other 
statistical methods and classifiers (e.g. LR, RF, MVA) can be fed with a diverse collection 
of data types. Regarding interpretability of the results, this is not the main concern of 
scientists according to Table 4. Very few of the works try to adapt the output of their 
models to make it understandable by doctors or use easily interpretable models (e.g. DT, 
BN). Whatever the case, the extensive use of image processing with CNN makes some 
models easier to understand than raw numerical results. 
3.5. Predict treatment outcome 
Cancer 
type 
AI 
approach 
Datasets Software Training 
dataset 
size 
Data 
types 
Exp? Reference 
CRC CNN Akershus 
University 
Hospital, Aker 
University 
Hospital, 
Gloucester 
Colorectal 
Cancer Study, 
VICTOR trial 
TensorFlow 12*106 Images No (Skrede et al., 
2020) 
RF Teikyo 
University 
Hospital, Gifo 
University 
Hospital 
unknown 54 Medical 
Records 
No (Tsuji et al., 
2012) 
RF, SVM, 
ANN, DT, 
KNN, GBM 
GSE19860, 
GSE28702, 
GSE72970 
caret, class, 
e1071, gbm, 
tree, 
randomForest, 
RSNNS 
50 Raw 
data 
No (Lu et al., 
2020) 
LR, DT, 
GBM 
BioStudies 
database 
Scikit-learn, R 800 Excel No (Y. Xu et al., 
2020) 
BN ACTUR 
database 
NCSS 5301 DB-
stored 
Yes (Steele et al., 
2014) 
medical 
records 
RF, ANN Genomics of 
Drug 
Sensitivity in 
Cancer portal 
Encog, 
randomForest 
38930 Raw 
data 
No (Menden et 
al., 2013) 
SVM GSE19860, 
GSE28702, 
GSE72970 
e1071 144 Raw 
data 
No (Lin, Qiu, 
Zhang, & 
Zhang, 2018) 
RF GSE52735, 
GSE62080, 
GSE69657 
limma, glmnet, 
Boruta, 
randomForest, 
pROC 
58 Raw 
data 
No (Gan et al., 
2019) 
SVM, LR unknown Orange 38 unknown No (Land, 
Margolis, 
Gottlieb, 
Yang, & 
Krupinski, 
2010) 
SVM Val d’Aurelle 
Regional 
Cancer Center 
MAS 5.0 5 to 19 Numbers No (Del Rio et 
al., 2007) 
Breast Diagonal 
LDA, KNN 
Nellie B. 
Connally 
Breast Center, 
M.D. 
Anderson 
Cancer 
Center, 
Instituto 
Nacional de 
Enfermedades 
dCHIP 133 Text, 
Numbers 
No (Hess et al., 
2006) 
Neoplásicas 
de Lima 
SVM, 
Recursive 
Feature 
Elimination 
University of 
Heidelberg 
e1071, ROC 52, 48 Numbers No (Thuerigen et 
al., 2006) 
LR unknown unknown 84 Numbers No (Harris et al., 
2007) 
Bladder DT University of 
Southern 
California 
SPSS 948 Numbers No (Mitra, 
Skinner, 
Miranda, & 
Daneshmand, 
2013) 
Blood LDA FRALLE93 
protocol 
unknown 32 Numbers No (Talby et al., 
2006) 
Renal SVM National 
Wilms Tumor 
Study-5 
e1071 250 Numbers No (C. C. Huang 
et al., 2009) 
Ovary Binary LR, 
Stochastic 
Regression 
Duke 
University 
Medical 
Center, H. Lee 
Moffitt Cancer 
Center and 
Research 
Institute 
Bioconductor 83 Numbers No (Dressman et 
al., 2007) 
Esophageal SVM unknown unknown 46 Text, 
Numbers 
No (Duong et al., 
2007) 
Lung DT, RF, 
ANN, SVM, 
LR, GBM 
(Belderbos et 
al., 2005), 
(Bots et al., 
2017), 
(Carvalho et 
al., 2016), 
(Janssens et 
al., 2012), 
(Jochems et 
al., 2017), 
(Kwint et al., 
2012), 
(Lustberg et 
al., 2016), 
Morin 
(forthcoming), 
(Oberije et al., 
2015), (Olling, 
Nyeng, & 
Wee, 2018), 
(Wijsman et 
al., 2015), 
(Wijsman et 
al., 2017) 
caret 156, 
137, 
363, 
179, 
327, 
139, 
922, 
257, 
548, 
131, 
149, 188 
Text Yes (Deist et al., 
2018) 
Head and 
Neck 
Meningioma 
Laryngeal 
Table 5. List of works presented in Section 3.5 about the prediction of therapy outcome in cancer 
patients. 
In the move towards personalised therapies, the prediction of therapy outcome is 
essential. In spite of the fact that several works where AI is used to estimate a tumour’s 
evolution after therapy for colorectal (Del Rio et al., 2007; Tsuji et al., 2012), breast (Harris 
et al., 2007; Hess et al., 2006; Thuerigen et al., 2006), blood (Talby et al., 2006), renal (C. 
C. Huang et al., 2009), ovary (Dressman et al., 2007) or oesophageal (Duong et al., 2007) 
cancer, this topic remains a major challenge for scientists. 
 
Classification, regression and clustering algorithms have frequently been used to resolve 
this sort of issue. As example of the classification method, a DT was implemented to 
diagnose and predict therapy outcome for bladder cancer patients using the SPSS 
statistical package (Mitra et al., 2013). The work showed how nearly 950 patients could be 
classified into three groups with different recurrence-free and overall survival probabilities. 
DTs have the advantage of being very intuitive and easy to interpret by medical doctors, 
which is one of the main aims of health-related MLs. A similar statistical analysis for 
classification purposes was carried out with BN implemented with Number Cruncher 
Statistical Systems (NCSS) on a dataset of CRC patients (Steele et al., 2014). In this case, 
the positive prediction rate ranged from 78 to 84 per cent when estimating recurrence for 
the training dataset extracted from the ACTUR database. The main limitation of this work 
is data reliability and consistency due the military nature of some institutions feeding the 
data source, which lack approved programs for cancer treatments. RF is another widely 
used recurrent classification algorithm that is already used to predict the response to 
FOLFOX (5-FU, leucovorin and oxaliplatin) therapy (Tsuji et al., 2012). The model was 
able to correctly predict 69.2% of cases in the test set. Relationships between genomic 
alterations and drug responses is a factor that could lead to enhanced individual therapies. 
Although both genomic features and chemical properties have been computationally 
analysed, there is still a lack of works studying both factors together. To shed some light 
on this topic, ANNs and RF were used to predict therapy outcomes (Menden et al., 2013). 
The core of this work was the implementation of a three-layer ANN. The inputs were 608 
cell lines and 111 drugs, a number between 1 and 30 hidden nodes were tested to find the 
best performing architecture and the IC50 predicted value was the only output. Note that 
the IC50 value is normalized in the range [0,1] by the sigmoid function added in the output 
layer. Based on the R2 performance metric, the model obtained 0.64 on the test dataset 
extracted from the GDSC portal, and 0.61 on an external validation dataset. Then, a RF 
implemented in R was developed to ascertain whether the ANN model could be improved 
but it resulted in a R2 of 0.59 on the blind test dataset, which is a slightly lower value than 
that achieved by the ANN model. Although the results look promising, the model has some 
limitations that could be overcome by adding more cell lines, epigenetics data and gene 
expression data as inputs. Classification algorithms could also help in identifying potential 
biomarkers too which is another topic that has received increasing attention in recent 
years. An R-implemented RF (Gan et al., 2019) for this task achieved 81% accuracy in the 
validation dataset. A feature selection step is carried out in this study before the 
classification. Reducing the dimension of the input makes the classifier faster and 
facilitates interpretation of the results by clinicians. 
 The diversity of classification and regression algorithms makes scientists wonder about the 
best choice to build new models and benchmark their own. To fairly assess some of the 
most typical classifiers an extensive study was carried out (Deist et al., 2018) with a set of 
algorithms. Six classifiers were evaluated on twelve datasets related to different cancers 
(lung, head, neck, meningioma, and laryngeal) using the AUC as a measure of which ones 
will work well in the future too. Although none of the algorithms stood out over the others, 
RF and Elastic Net Logistic Regression (ENLR) exhibited a higher discriminative power in 
chemo and radiotherapy outcome. Therefore, it is suggested that they might be the first 
choice when building classification models. The authors also claim that RF and ENLR 
should be the preferred option against which custom models should be compared. 
 
Many other supervised learning approaches can be found in the literature. Most of the 
cases exploit datasets from the National Center for Biotechnology Information (NCBI) or 
collected from local institutions. SVMs represent a method that is commonly adopted to 
predict tumour progress after therapy and is especially helpful when predicting FOLFOX 
therapy results in CRC patients because this type of algorithm usually works with images. 
When working alone, SVM reached a positive prediction rate of 85.4% (Lin et al., 2018), 
which is similar to that obtained by RF. But SVM can also be combined with LR to provide 
a novel scoring method to measure the tumour size response to therapy, as it outperforms 
the traditional WHO and RECIST measurements (Land et al., 2010). 
 
Recent studies assessed a variety of ML methods in CRC prediction scenarios. Lu (Lu et 
al., 2020) compared six models implemented with R packages in a FOLFOX response 
prediction task. The models represented the following approaches: RF, SVM, ANN, DT, 
KNN, and GBM. The experimental tests showed that RF and SVM were the most accurate 
methods when predicting FOLFOX outcome. Unfortunately, their performance fell off when 
predicting other therapies such as FOLFIRI (5-FU, leucovorin, and irinotecan), therefore 
their application to future patients is limited. The reason for this reduction in performance 
when using alternative therapies seems to be related with the aforementioned use of 
unexplored datasets with different characteristics, which would indicate a close 
relationship between the model and the training data. The third best-ranked classifier was 
the ANN model, whose accuracy was close to that of RF and SVM but was more 
consistent when confronted with other therapies. This result demonstrates that ANNs 
constitute a powerful predictive tool for future CRC studies. In another work (Y. Xu et al., 
2020) the authors assessed four ML methods (LR, DT, GBM, and Light GBM) and found 
GBM and Light GBM to be more accurate than the others. This evidence leads us to think 
that GBM probably gain in importance in the near future. Finally, the rapid development of 
ANN and its variants (e.g. recurrent neural networks, convolutional neural networks, 
adversarial neural networks) has encouraged scientists to develop enhanced and more 
powerful networks capable of profiting from HPC architectures. As a result of that 
evolution, several libraries (e.g. TensorFlow) are widely used nowadays. Tensor-based 
networks are especially useful for image processing due to their ability to exploit all the 
computing power of GPUs to analyse images in a parallel manner. This novel ML 
paradigm has been used to build a CNN model that anticipates the outcome after 
resection based on a dataset of 12 million images (Skrede et al., 2020). 
The poor interpretability of the results is a challenge that needs to be faced. Raw 
estimations or complicated charts might be unintelligible to doctors and may render any 
ML algorithm worthless for practical reasons. The data types feeding ML systems intended 
to predict therapy outcomes are very different, ranging from binary data to well-structured 
records (e.g. Excel, CSV, database records). In this step, the application of image 
processing through CNN is not so frequent, as explained in the previous section, but still 
constitutes the preferred approach when manipulating images, as can be seen in Table 5.  
3.6. Predicting likelihood of survival 
 
Once cancer has been diagnosed, classified, and treated, the next questions are how the 
tumour will evolve and how likely is the patient’s survival. The former was already 
answered in section 3.3, so this section will focus on the available ML methods for the 
latter. Note that the works introduced in section 3.5 not necessarily predict the survival 
chances in months, for example, but is more likely to focus on how the treatment will 
reduce the tumour size. The prognostication of a patient’s survivability is not easy and 
depends on many factors, such as the type of cancer and the stage. Fortunately, ML can 
help doctors evaluate survival chances by analysing several biomarkers in a systematic 
manner. With the aim of answering this question, Zhu (Zhu, Xie, Han, & Guo, 2020) 
summarizes an extensive collection of works concerning the use of DL in cancer 
prognosis, including some that estimate the survival likelihood and even the survival time. 
 
Cancer 
type 
AI 
approach 
Datasets Software Training 
dataset 
size 
Data 
types 
Exp? Reference 
Breast SVM (van de 
Vijver et 
al., 2002) 
unknown 295 Numbers No (X. Xu, 
Zhang, Zou, 
Wang, & Li, 
2012) 
BN (Van’t 
Veer et 
al., 2002) 
unknown 97 Numbers Yes (Gevaert, 
De Smet, 
Timmerman, 
Moreau, & 
De Moor, 
2006) 
SSL SEER 
database 
unknown 162500 DB-
stored 
medical 
records 
No (K. Park et 
al., 2013) 
SSL Co-
training 
SEER 
database 
unknown 162500 DB-
stored 
medical 
records 
No (J. Kim & 
Shin, 2013) 
ANN, LR, 
DT 
SEER 
database 
unknown 200000 DB-
stored 
medical 
records 
Yes (Delen, 
Walker, & 
Kadam, 
2005) 
Oral SVM unknown unknown 69 unknown No (Rosado, 
Lequerica-
Fernandez, 
Villallain, 
Peña, et al., 
2013) 
Any ANN unknown unknown 440 unknown No (Y.-C. Chen, 
Ke, & Chiu, 
2014) 
Lung Linear 
Regression, 
DT, SVM, 
GBM, 
Customa 
SEER 
database 
R 7830 DB-
stored 
medical 
records 
Yes (Lynch et 
al., 2017) 
CRC CNN, RNN Helsinki 
University 
Central 
Hospital 
Keras 420 Images Yes (Bychkov et 
al., 2018) 
Brain CNN TCGA, 
South 
Australian 
public 
hospital 
system 
Keras, 
Tensorflow 
679 Images Yes (Zadeh 
Shirazi et 
al., 2020) 
Prostate DT, BN, 
Cox 
The 
Methodist 
Hospital 
S-PLUS 1050 Text Yes (Zupan, 
Demšar, 
Kattan, 
Beck, & 
Bratko, 
2000) 
Table 6. Summary of works about ML and the likelihood of survival 
a A custom ensemble of methods. 
 
According to a recent review (Kourou et al., 2015), SVMs provide the most accurate 
predictions of cancer survival. Although all the analysed studies are trained on small 
datasets, they are able to reach up to 98% and 97% accuracy in oral (Rosado, Lequerica-
Fernandez, Villallain, Pena, et al., 2013) and breast (X. Xu et al., 2012) cancer, 
respectively. Other approaches such as ANNs (Tseng et al., 2014) and BNs (Gevaert et 
al., 2006) are showing good results as well, attaining more than 83% accuracy, and both 
are expected to gain in importance in coming years. On the other hand, SSL, which only 
works with a few labelled samples, has emerged as a feasible alternative to the classic 
supervised and unsupervised learning paradigms but, as its results show (71% and 76% 
accuracy reported by (K. Park et al., 2013), and (J. Kim & Shin, 2013)), predictive capacity 
of this approach still has to be improved. Nevertheless, another study on lung cancer that 
used similar ML techniques yielded different results (Lynch et al., 2017). The authors 
evaluated linear regression, DT, SVM, GBM, and a custom ensemble, finding that GBM 
was the most accurate model in terms of root mean square error (RMSE). All the models 
were implemented in R language and trained on SEER database. In recent decades, 
cancer has been one of the preferred fields for the assessment of ML models to predict 
survival likelihood. An analysis of survivability in prostate cancer patients (Zupan et al., 
2000) was carried out using three non-linear statistical methods: DT, BN and Cox (Cox, 
1972). This work represents a case study that aims to demonstrate that ML classifiers are 
useful for estimating a patient’s survival chances, a process that is receiving increasing 
attention from ML experts. The authors conclude that ML statistical models could be 
helpful in the near future for predicting survival and other issues such as the probability of 
recurrence in cancer patients. 
The new wave of ML is dominated by ANNs and their subtypes such as convolutional, 
recurrent or adversarial neural networks, among others. CRC can also profit from ANNs to 
predict survival chances, especially when the input datasets are image collections and the 
use of CNNs is advantageous. A recent work (Bychkov et al., 2018) described the training 
of a DL system, built on convolutional and recurrent neural networks, to classify tumour 
images. Such classifications of tumour images are a frequent way of predicting tumour 
evolution and, consequently, evaluating survival chances. It is worth mentioning that the 
classifier used by these authors ran on a GPU to accelerate the processing and deliver the 
results in a short time. GPUs can speed up CNN calculations dramatically, which is a huge 
advantage due to the large number of samples that CNNs usually deal with and the high 
number of layers they have. Other cancer types also take advantage of CNNs and exploit 
GPU computing power. Such is the case with brain cancer, for which condition patient 
survival can be estimated by means of the recently published classifier DeepSurvNet 
(Zadeh Shirazi et al., 2020). DeepSurvNet builds CNN models implemented with Keras 
and TensorFlow libraries, which are trained with a dataset from the TCGA Program 
(Weinstein et al., 2013). The models classify the patients into four groups, each with an 
estimated overall survival. 
The use of ML approaches whose output can be graphically represented, such as BN, DT 
and CNN, facilitates the interpretation of survival chances by healthcare professionals. The 
easy interpretation of results should always be taken as a requirement when ML is to be 
applied in a context outside computer sciences. It is also worth noting that medical records 
extracted from public databases are a common input (Hutter & Zenklusen, 2018; SEER, 
2020) when evaluating survivability, which indicates that long-term well-structured data are 
the most useful data source to predict survival chances. 
4. Software and datasets 
In this section, we will summarize the most relevant technical details extracted from the 
above-mentioned works, such as the software tools created, the availability of the source 
code, the use of HPC platforms and the main features of the datasets. Figure 2 
summarises the approaches applied at every stage. It can be observed that ANN, LR and 
SVM are the most common methods in cancer research. RF, BN, DT, KNN, GBM and 
CNN are also used frequently but are not reported in all the tasks. 
 Fig. 2. Graphical summary of ML methods being applied in cancer research tasks. Super 
indices in the central figure represent the number of steps in which that approach is 
reported. No index means that the approach is reported in all the tasks.  
 
4.1. Software tools 
In Tables 1-6 we have enumerated a number of libraries and frameworks frequently used 
for developing ML models. There is a clear trend to implement models in R and Python 
languages. R is a good choice for rapid development due to the diverse collection of 
packages it provides (e.g. caret, e1071, Bioconductor) and the many possibilities it offers 
to create different models, including SVM, RF and DT, among others. Therefore, its 
simplicity and flexibility make it an attractive alternative for several scientists. The other 
preferred option is Python and, in particular, frameworks like TensorFlow and PyTorch. 
Tensor-based frameworks have gained in importance in recent years supported by the 
rapid development of GPUs, which are a very suitable hardware solution for tensored 
calculations. While the use of R implementations has been mentioned for several years, 
publications reporting works in Python-based frameworks tend to date from 2017. This 
confirms the intuition that the development of GPUs, and more generally HPC, will be 
closely connected with the advances achieved in the performance of ML algorithms in the 
near future.  
Many statistical tools are less frequently used. This group of statistical methods is 
composed of tools such as Matlab, SPSS, Caffe and Weka. Although they are not so 
powerful as programming languages, they offer many statistical features that allow the 
rapid development of models, including LR, SVM, ANN and BN. Furthermore, the 
indicated tools are well established in the academic world, and so many scientists are 
familiar with them and their reliability has been extensively proved. 
Despite being well known and a very stable language, Java is barely used in this context. 
Only the Encog and MLlib libraries are reported in the works. There may be many reasons 
to explain this but the main ones are probably that Java is usually considered slower than 
other languages and that the users do not have the programming skills required by this 
tool. 
Task Reference Code availability 
Predict 
cancer risk 
(Behravan et 
al., 2018) 
https://github.com/hambeh/breast-cancer-risk-prediction  
(Celli et al., 
2018) 
https://github.com/fcproj/BIGBIOCL  
Predict 
progression 
(Auslander 
et al., 2019) 
https://github.com/noamaus/LSTM-Mutational-series  
(Bhalla et 
al., 2019) 
https://webs.iiitd.edu.in/raghava/cancerspp/  
Predict 
recurrence 
(W. Kim et 
al., 2012) 
http://ami.ajou.ac.kr/bcr/ 
Estimate 
drug 
synergy 
(Musen et 
al., 1996) 
https://protege.stanford.edu/  
(Celebi et 
al., 2019) 
https://github.com/rcelebi/dream-drugcombo 
https://www.synapse.org/#!Synapse:syn5605365/wiki/394725 
(Keshava et 
al., 2019) 
https://github.com/szen95/SEABED  
(Preuer et 
al., 2018) 
http://www.bioinf.jku.at/software/DeepSynergy/  
(L.-C. Chen, 
Papandreou, 
Kokkinos, et 
al., 2017) 
https://github.com/tensorflow/models/tree/master/research/deeplab  
(L.-C. Chen, 
Papandreou, 
Schroff, et 
al., 2017) 
http://liangchiehchen.com/projects/DeepLab.html  
Predict 
therapy 
outcome 
(Deist et al., 
2018) 
https://github.com/timodeist/classifier_selection_code  
Predict 
survival 
(K. Park et 
al., 2013) 
http://embio.yonsei.ac.kr/̃Park/ssl.php  
Table 7. List of code repositories or servers listed in the manuscript. 
Few authors share the source code of their models with the community (see Table 7). 
Sometimes they prefer to develop and release a novel tool providing the obtained models 
through a web interface (Bhalla et al., 2019; Preuer et al., 2018). While this is an 
understandable decision it hinders understanding of the models by external users. 
However, other researchers freely share their codes, usually on github, and allow others to 
study and analyse how they are developed. From an objective point of view, this is the 
preferred solution because it allows existing codes to be better understood, improved and 
optimized, as well as the development of new models from a solid base. 
4.2. HPC infrastructures 
While HPC platforms are rarely reported in the analysed papers, the use of GPUs has 
increasingly been mentioned recent years (e.g. Bychkov et al., 2018; Zadeh Shirazi et al., 
2020). The recent development of Tensor-based frameworks and libraries for ML, e.g. 
TensorFlow, Keras, PyTorch, has promoted the use of GPUs for programming ML 
algorithms (Bychkov et al., 2018; L.-C. Chen, Papandreou, Kokkinos, et al., 2017; Y.-C. 
Chen et al., 2014; Nguyen et al., 2019; Preuer et al., 2018; Skrede et al., 2020; Y. Xu et 
al., 2020; Zadeh Shirazi et al., 2020). The rapid integration of GPU computing in ML 
strongly suggests that faster ML algorithms will emerge in coming years, resulting in the 
ability to handle even larger training datasets. 
Please note that, although references to other HPC paradigms have not been found in this 
revision, it is very possible that other authors have leveraged HPC platforms (e.g. parallel 
computing) in their works. 
4.3. Datasets 
We can broadly classify the input datasets into two major groups: i) those obtained from 
publicly available databases; and ii) those collected from institutions (e.g. hospitals or 
universities). Although both online and custom approaches are valid, public datasets 
facilitate the reproducibility of the experiments. SEER and TCGA databases are typically 
used in cancer research. 
 
Leaving their source aside, we have focused on two properties of the datasets: the data 
types they contain and the size of the training dataset. The data types vary widely between 
works, including in terms of the text, images, medical records and binary data. Numerical 
values are the preferred option for feeding ML algorithms because they mostly work on 
numerical calculations. As can be observed in Tables 1-6, when public or private 
institutions are responsible for collecting data, they usually work with numerical data. Also, 
text inputs are widely used, probably because they can be easily translated into numerical 
values. Images are typically used to feed CNNs due to the ability of this type of network to 
apply sequential filters on images and extract patterns. This is also a frequent option 
because many hospitals and universities have easy access to historical images from 
scans, tomography or mammography. 
 
 Fig. 3. Reported dataset size by algorithm. 
 
Structured information is more suitable for ML than unstructured. Usually, ML algorithms 
receive a set of well-defined inputs, which they evaluate and weigh to make predictions. 
Therefore, when the inputs are clearly defined, the models can be easily developed (e.g. 
BN, ANN, LR, DT). This is the case of databases, such as ACTUR, SEER and TCGA, and 
other datasets where the fields are undoubtedly separated. 
 
The second key feature of the analysed datasets is their size, which ranges from tens to 
millions of samples. In general terms, neural networks (ANN, CNN, RNN) handle the 
largest datasets (e.g. 200000, 463080, 235673 and 12x106 samples). Although a large 
number of samples may seem an advantage, their sheer numbers can slow the system 
down during training. Thus, finding a good balance between dataset size and learning 
capability is required. By contrast, the simplest approaches seem to need fewer data to 
learn as can be inferred from the fact that the smallest datasets (less than 100 training 
samples) are used by traditional methods such as RF and SVM. Figure 3 shows the 
reported dataset size used in ML algorithms. 
5. Conclusions and outlook 
Decision-making is one of the main challenges in modern medicine is exercised at every 
stage of a disease’s lifecycle, from diagnosis to the prediction of recurrence. Traditionally, 
doctors have trusted their experience to choose the best option for individual patients. 
However, they cannot be expected to recall all the details of all the patients they have 
treated in the past, which clouds their ability to recognise patterns in similar situations. This 
is where computational help is required. 
 
In recent years, AI, and, more specifically, machine and deep learning, have looked at 
medical decision-making. In this context, anti-cancer medicine has been found to be a 
favourite playground due to the high mortality rate of the disease, the increasing number of 
cases expected in the forthcoming years and the vast amount of data available in 
databases of hospitals, universities and research centres. The diversity of existing cancer 
types encourages experiments with different ML algorithms aimed at the same target. In 
this review, we have analysed the generalised use of ML in cancer research but always 
bearing in mind CRC.  
 
CRC is the fourth cause of mortality due to cancer worldwide and the number of cases that 
are expected to appear in the next decade is not promising, making it a suitable target for 
ML. Any ML algorithm can be applied on CRC research ranging from the simplest (e.g. LR, 
SVM, KNN) to the most complex ones (e.g. CNN, DNN) but it has been observed that 
ANN, LR and SVM are frequently reported in any task related with decision-making (risk 
prediction, recurrence prediction, tumour progression, estimation of drug synergy, therapy 
outcomes and survival time estimates). Moreover, RF, GBM, BN, DT, KNN and CNN are 
often applied in many cases.  
 
There is no clear relationship between the selected approach and the type of data feeding 
the system. However, CNN is clearly the preferred option when manipulating medical 
images. It is clear that well-structured records with text or numerical fields are the simplest 
and favourite options when available. The dataset size is another key factor when training 
ML or DL systems. If the dataset is too small, the ML system will face difficulties related 
with learning and generalizing, whereas excessively large datasets may slow down the 
training phase. Thus, finding the optimal dataset size remains a challenge. As regards 
performance in terms of computing time, his key concern for scientists has resulted in the 
emergence of libraries and frameworks specifically focused on profiting from HPC 
facilities, such as GPUs. GPU are the preferred architecture for running CNN calculations, 
and NVIDIA has placed its bet on this technology becoming the world’s leading 
manufacturer. 
 
Explainability has been identified as the third key point to worry about, although it is no 
less important than the typical accuracy and performance metrics. The importance of 
explainability stems from the fact that ML is increasingly used in a medical context, where 
users are often inexperienced in interpreting AI metrics and results. Consequently, output 
must be translated into a language that physicians can understand. It has been perceived 
that explainability is still barely considered in most of the works analysed, suggesting that it 
is a factor that can be improved in order to “democratise” AI in many other areas. To 
improve the explainability of systems, feature selection methods are sometimes applied 
before classification. This technique helps to reduce the input size leading to faster 
classification and providing a more interpretable output. Some ML algorithms such as BN 
and DT are especially appropriate for this purpose because they return labelled directed 
graphs which are very easy to read and interpret. 
 
In short, we predict a bright future of ML and DL in medical decision-making but the results 
must be more explainable in this or any other context. Identifying the optimal training 
dataset size is another factor that deserves further study. Fortunately, the rapid 
development of HPC will make ML systems more efficient and enable them to transform 
the overwhelming quantity of historical data stored in public and private databases into 
real, reliable and valuable knowledge. 
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